Please wait while we open this resource.
K
Clinical reviews
SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence
University of Mississippi Medical Center, Charité Universitätsmedizin Berlin, Baylor Scott and White Research Institute
PDF20239 pages635 KB
Sodium-glucose co-transporter 2 (SGLT-2) inhibitors have emerged as a significant component of guideline-directed medical therapy for heart failure (HF) with reduced ejection fraction. Recent trials indicate that these medications can substantially reduce adverse cardiovascular outcomes in patients with HF, including those with mildly reduced and preserved ejection fraction. The review also addresses the metabolic effects of SGLT-2 inhibitors and their safety profile, including potential adverse events associated with their use.
Sign in to open
Ask this resource
Answers use this document only.
Your first question is free.
More like this
Resources from the same specialty and type. Curated links will replace these when added.
Clinical Resources
Documents that extend or complement this resource.
SURVIVAL AFTER INITIAL STRESS TESTING VS ANATOMIC TESTING IN SUSPECTED CORONARY ARTERY DISEASE
Same clinical topic · Cardiology
PRACTICAL CARDIO-ONCOLOGY
Same clinical topic · Cardiology
OXFORD CARDIOLOGY LIBRARY: Hypertension
Same clinical topic · Cardiology
CARDIAC INVOLVEMENT IN PARASITIC INFECTIONS
Same clinical topic · Cardiology
The Athlete’s ECG
Same clinical topic · Cardiology
Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review
Same clinical topic · Cardiology
Current ECG Aspects of Interatrial Block
Same clinical topic · Cardiology
Arrhythmic mitral valve prolapse in 2023: Evidence-based update
Same clinical topic · Cardiology
INTERPRETING THE NORMAL PACEMAKER
Same clinical topic · Cardiology